Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TMEM132E divergent transcript (TMEM132E-DT), also known as C17orf102 and FLJ44815, is a long non-coding RNA (lncRNA) gene located near the TMEM132E protein-coding gene on chromosome 17. According to the HUGO Gene Nomenclature Committee, divergent transcripts are lncRNAs found within 300-500 nucleotides of a protein-coding gene on the opposite strand, often with unclear function[5][7]. TMEM132E-DT is not known to encode a functional protein and is classified as an uncharacterized RNA gene[5][10]. There is currently no direct evidence to suggest that TMEM132E-DT acts as a receptor, enzyme, transporter, or other classical therapeutic target class, and no interacting drugs or established mechanisms of action have been described in the literature[5][10][11]. It has been weakly associated with Fuchs' endothelial dystrophy, but its functional role, mechanisms, or biomarker utility have not been established[5]. Therefore, TMEM132E-DT is best considered as a non-protein-coding transcript with unknown biological function and limited, if any, disease association.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TMEM132E divergent transcript (TMEM132E-DT).